Insmed Inc (INSM)vsIO Biotech Inc (IOBT)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
IOBT
IO Biotech Inc
$0.19
-8.61%
HEALTHCARE · Cap: $12.71M
Smart Verdict
WallStSmart Research — data-driven comparison
IOBT leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
IOBT
Avoid19
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Trading at 19.1x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : IOBT
IOBT has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : IOBT
The primary concerns for IOBT are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while IOBT is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
IOBT generates stronger free cash flow (-18M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 19/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
IO Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
IO Biotech Inc. is a clinical-stage biotechnology firm focused on pioneering innovative immunotherapy solutions to bolster the immune response against cancer. Utilizing its novel immune-oncology platform, the company aims to stimulate and enhance the body’s innate defenses to target tumor cells. With a robust pipeline of therapeutic candidates progressing through clinical trials, IO Biotech is well-positioned to meet pressing unmet needs in oncology, particularly for solid tumors. The company's dedication to rigorous scientific research underscores its potential to transform the standards of cancer treatment and significantly improve patient outcomes.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?